Search

Anxious and depressive symptoms often co-occur and are associated with difficulties in academic, social, and emotional areas of functioning. The current study identified the factor structure and profiles of symptoms of anxiety and depression among 169 Black early adolescents in sixth through eighth grade (Mage = 12.6 years; 50% female) using confirmatory factor analyses (CFAs) and latent profile analyses (LPA), respectively. CFAs supported a six-factor model for depressive symptoms (i.e., dysphoria, social problems, externalizing, self-deprecation, biological dysregulation, and school problems) and a four-factor model for anxiety symptoms (i.e., social evaluation, worry, affective response, and physiological symptoms/sleep problems). These factors formed the profiles for the LPA analyses, and results supported a three-profile solution that included: (a) a low-severity group who reported few anxious or depressive symptoms, (b) a group who reported high levels of externalizing behaviors and moderate levels of school and social evaluation problems, and (c) a group who reported high levels of social evaluation problems and physiological/sleep anxiety. The three groups differed significantly in their ratings of anger regulation difficulties (i.e., anger emotion regulation coping, anger inhibition, and anger dysregulated expression) and their perceptions of the quality of school interpersonal relationships (i.e., student-teacher relationships and student-student relationships). These findings add to our knowledge about how patterns of depressive and anxious symptoms present for Black youth during adolescence and have important implications for the conceptualization, treatment, and prevention of anxiety and depression using culturally sensitive approaches. Highlights: The experience and presentation of depressive and anxious symptoms differed for Black youth. Factor structures of depression and anxiety measures were confirmed prior to running latent profile analyses. Three profiles of anxious and depressive symptom dimensions were identified. Profiles differed in youths' ratings of anger regulation difficulties and perceptions of the quality of school interpersonal relationships. [ABSTRACT FROM AUTHOR]

Background: Patients with vitiligo experience reduced quality of life. Objective: To comprehensively describe the available evidence for psychosocial burden in vitiligo. Methods: A systematic review of observational studies and clinical trials identified using PubMed, EMBASE, Scopus, and the Cochrane databases was performed through 1 March, 2021, to assess psychosocial comorbidities in vitiligo. Two independent reviewers performed an assessment of articles and extracted data for qualitative synthesis. Results: Included studies (N = 168) were published between 1979 and 1 March, 2021; 72.6% were published since 2010. Disorders including or related to depression (41 studies, 0.1–62.3%) and anxiety (20 studies, 1.9–67.9%) were the most commonly reported. The most prevalent psychosocial comorbidities were feelings of stigmatization (eight studies, 17.3–100%), adjustment disorders (12 studies, 4–93.9%), sleep disturbance (seven studies, 4.6–89.0%), relationship difficulties including sexual dysfunction (ten studies, 2.0–81.8%), and avoidance or restriction behavior (12.5–76%). The prevalence of most psychosocial comorbidities was significantly higher vs healthy individuals. Factors associated with a significantly higher burden included female sex, visible or genital lesions, age < 30 years (particularly adolescents), and greater body surface area involvement, among others. The most commonly reported patient coping strategy was lesion concealment. Limitations: Available studies were heterogeneous and often had limited details; additionally, publication bias is possible. Conclusions: The results of this systematic review show that vitiligo greatly affects psychosocial well-being. The extent of psychosocial comorbidities supports the use of multidisciplinary treatment strategies and education to address the vitiligo-associated burden of disease. Protocol Registration: PROSPERO (CRD42020162223). [ABSTRACT FROM AUTHOR]

Hyperhemolysis syndrome (HHS) is an uncommon transfusion reaction described in several hematologic disorders, including sickle cell disease (SCD). HHS is characterized by a decline in hemoglobin (Hb) values below pre-transfusion levels following transfusion of red blood cells (RBCs), coupled with laboratory markers consistent with hemolysis. The proposed pathophysiologic mechanisms underlying HHS include increased phosphatidylserine expression, macrophage activation, and complement dysregulation. Many pathophysiologic mechanisms thought to contribute to HHS have been similarly described in cases of severe COVID-19. A 28-year-old male with a history of HbSS presented with shortness of breath, right-sided chest pain, and a two-day history of fever. Polymerase chain reaction (PCR) detected SARS-CoV-2 infection with the omicron variant. The patient required an RBC transfusion (pre-transfusion hemoglobin [Hb]5.8 g/dL) with an immediate post-transfusion Hb of 6.3 g/dL. However, Hb rapidly declined to 1.7 g/dL, and lactate dehydrogenase (LDH) rose to 8701 u/L. The absolute reticulocyte count of 538 × 109/L correspondingly fell to 29 × 109/L. Despite additional RBC transfusions and initiation of immunosuppressive therapy, he expired on Day 9(D9). Given the similarities in their proposed pathophysiology, patients with SCD and concomitant SARS-CoV-2 infection may be predisposed to developing HHS. [ABSTRACT FROM AUTHOR]